FDA accepts UCB’s sBLA for Bimzelx
Betsy Goodfellow | April 5, 2024 | News story | Medical Communications | Bimzelx, FDA, Pharmacy, UCB, sBLA
UCB has announced that the US Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for Bimzelx (bimekizumab-bkzx), for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS).
An additional sBLA for bimekizumab-bkzx 2ml device presentations has also been accepted for review.
The drug is an IL-17A and IL-17F inhibitor, and these recent acceptances are only two of five sBLAs accepted by the FDA for this drug in 2024. Previously, the FDA has accepted applications in psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis. It has also been approved in the US for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Emmanuel Caeymaex, executive vice president of immunology solutions and head of US at UCB, commented: “We are excited to share the progress on our FDA applications. The most recent sBLA seeks approval for bimekizumab-bkzx in moderate to severe hidradenitis suppurativa, and is aligned to our goal of expanding the reach of bimekizumab to more patients living with IL-17 mediated diseases. In addition, the sBLA for the 2mL device presentations aims to offer increased convenience for patients. Today, one dose of bimekizumab in moderate to severe plaque psoriasis, is administered as two 1mL injections. Approval of the 2mL device presentations would mean that patients would have an alternative one injection regimen option.”
Betsy Goodfellow
Related Content
UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …
